IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.508
AS - Asia 2.031
EU - Europa 1.547
SA - Sud America 330
AF - Africa 30
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.452
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.444
CN - Cina 917
SG - Singapore 539
IE - Irlanda 506
HK - Hong Kong 298
BR - Brasile 271
RU - Federazione Russa 264
DE - Germania 196
FI - Finlandia 152
VN - Vietnam 108
IT - Italia 107
GB - Regno Unito 73
UA - Ucraina 57
IN - India 35
CA - Canada 31
FR - Francia 29
SE - Svezia 29
AR - Argentina 25
MX - Messico 25
ES - Italia 22
PL - Polonia 22
JP - Giappone 20
ZA - Sudafrica 19
BD - Bangladesh 17
AT - Austria 16
BE - Belgio 14
TR - Turchia 14
NL - Olanda 12
LT - Lituania 11
CO - Colombia 8
EC - Ecuador 8
ID - Indonesia 8
IQ - Iraq 7
LB - Libano 7
PK - Pakistan 7
SA - Arabia Saudita 6
UY - Uruguay 6
AZ - Azerbaigian 5
BG - Bulgaria 5
JO - Giordania 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
CL - Cile 4
IR - Iran 4
MA - Marocco 4
NO - Norvegia 4
PY - Paraguay 4
TH - Thailandia 4
UZ - Uzbekistan 4
AL - Albania 3
AM - Armenia 3
AU - Australia 3
BN - Brunei Darussalam 3
JM - Giamaica 3
KR - Corea 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
GA - Gabon 2
HN - Honduras 2
LU - Lussemburgo 2
MK - Macedonia 2
MU - Mauritius 2
MY - Malesia 2
PE - Perù 2
RO - Romania 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
IS - Islanda 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TL - Timor Orientale 1
TN - Tunisia 1
TW - Taiwan 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.452
Salva come PNG Salva come JPEG
Città #
Dublin 506
Chandler 349
Hong Kong 293
Dallas 266
Singapore 264
Ashburn 244
Beijing 227
Nanjing 158
Boardman 99
Jacksonville 94
Helsinki 93
Los Angeles 86
Princeton 73
Lawrence 68
New York 61
Munich 58
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Buffalo 49
Redondo Beach 49
Shanghai 47
Shenyang 42
Ho Chi Minh City 40
Jiaxing 38
Moscow 36
Hebei 35
Changsha 34
Pavia 34
São Paulo 33
Hangzhou 31
Hanoi 30
Tianjin 24
Tokyo 20
Warsaw 20
Denver 18
London 18
The Dalles 18
Milan 17
Nuremberg 17
Poplar 16
Turku 16
Woodbridge 16
Johannesburg 15
Norwalk 15
Redwood City 15
Seattle 15
Brussels 14
Falkenstein 14
Orem 14
San Francisco 14
Mexico City 13
Brooklyn 12
Chicago 12
Atlanta 11
Chennai 11
Piscataway 11
Santa Clara 11
Stockholm 11
Toronto 11
Montreal 10
Ankara 9
Belo Horizonte 9
Fairfield 9
Frankfurt am Main 9
Phoenix 9
Washington 9
Beirut 7
Houston 7
Rio de Janeiro 7
Vienna 7
Amsterdam 6
Boston 6
Brasília 6
Charlotte 6
Guangzhou 6
Haiphong 6
Hyderabad 6
Manaus 6
Tamm 6
Zhengzhou 6
Amman 5
Biên Hòa 5
Curitiba 5
Düsseldorf 5
Fortaleza 5
Montevideo 5
Pune 5
Riyadh 5
San Jose 5
Baku 4
Columbus 4
Falls Church 4
Goiânia 4
Miami 4
Newark 4
Ningbo 4
Querétaro 4
Secaucus 4
Totale 4.304
Salva come PNG Salva come JPEG
Nome #
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 128
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 110
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 107
Bone marrow amyloidosis. 105
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 98
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 98
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 97
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 96
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 96
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 96
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 95
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 94
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 93
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 92
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 92
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 91
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 91
Prognostication of survival and progression to dialysis in AA amyloidosis 87
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 85
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 83
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 83
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 79
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 79
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 79
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 78
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 78
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 76
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 76
Regulated expression of amyloidogenic immunoglobulin light chains in mice 75
A case of monoclonal gammopathy of renal significance 75
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 73
Cells and prions: A license to replicate 72
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 72
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 71
Cystatin F is a biomarker of prion pathogenesis in mice 70
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 70
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 70
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 69
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 69
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 69
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 68
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 68
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 67
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 65
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 65
Prion protein and Ab-related synaptic toxicity impairment 65
A neuroprotective role for microglia in prion diseases 63
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 62
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 62
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 60
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 60
Development and Validation of Staging Systems for AA Amyloidosis 58
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 58
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 58
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 57
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 55
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 55
Structure-based drug design identifies polythiophenes as antiprion compounds 55
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 55
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 55
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 55
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 54
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 53
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 52
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 52
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 52
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 51
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 50
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 50
Systemic amyloidosis: novel therapies and role of biomarkers 49
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 47
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 47
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 47
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 46
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 45
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 44
The workings of the amyloid diseases. 44
Author Correction: The dengue-specific immune response and antibody identification with machine learning 43
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 43
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 42
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 42
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 42
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 42
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 41
The Priority position paper: Protecting Europe's food chain from prions 41
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 41
The immunobiology of prion diseases 40
Management of the elderly patient with AL amyloidosis 37
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 36
SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies 35
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 34
Redirecting proteoxicity 32
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 31
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 29
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 29
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis 29
New Insights Into a Multifaceted Disease 29
Mining the amyloid-plaque proteome to uncover disease mechanisms in renal amyloidoses 28
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 28
Renal amyloidoses 26
Totale 6.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.440
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.440
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 17 11 42 8 17 16 2
2021/2022280 3 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/20251.541 28 110 12 37 17 119 94 97 401 69 187 370
2025/20262.185 283 271 371 507 606 147 0 0 0 0 0 0
Totale 6.654